Gilead Exec VP-Commercial Operations Joins From Amgen
This article was originally published in The Pink Sheet Daily
Kevin Young will oversee global commercial operations and strategy for Gilead’s product portfolio, including the launch of the HIV combination therapy Truvada. At Amgen, he headed the U.S. Inflammation Business Unit and oversaw the relaunch of Enbrel.
You may also be interested in...
The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.